FRONT AND CENTER

All images in this brochure are actor portrayals.

Adult females with ADHD...

- ADHD diagnoses are rising among adults—particularly among women[1,2]
- The percentage of women newly diagnosed with ADHD between 23 and 29 years of age and between 30 and 49 years of age nearly doubled from 2020 to 2022[1]
- According to MarketScan Commercial data research (2016 to 2021), ADHD treatment rates rose rapidly in women of childbearing age[2]
- Many women are diagnosed with ADHD and treated during their reproductive years, which can lead to management implications during pregnancy and the postpartum period[3]

Abbreviation: ADHD, attention-deficit/hyperactivity disorder.

FRONT AND CENTER

Adult females with ADHD

ADHD market data[4]



- Adult females (20+ yrs) continue to make up the largest share of ADHD Rxs: **41%**[4]

IQVIA NPA Extended Insights, R12M as of 6/2025.

Nonstimulant prescription growth for adult females (20+ yrs) outpaced stimulant prescription growth for adult females (20+ yrs) by 5.6 times.[4]

IQVIA NPA Extended Insights, MAT 06/2025 vs MAT 06/2023.

Qelbree...a different ADHD approach[5-10]

Qelbree—the only ADHD treatment with serotonin (5-HT_{2C}) pharmacodynamics approved in FDA product labeling[5-11]

Abbreviation: FDA, US Food and Drug Administration.

INDICATION

Qelbree is indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

ONCE-DAILY Qelbree® viloxazine extended-release capsules 100 mg 150 mg 200 mg

Please see full Important Safety Information on page 8.

FRONT AND CENTER

Consider the many needs of your adult female patients with ADHD[5]

Phase III clinical trial designed to establish efficacy and safety in male and female adults[5]

Overview: clinical trial, study design, and methodology[5,12]

Study P306: Adults, 18 to 65 years of age[5,12]



Study medication: flexible dosing (200 mg/day to 600 mg/day) or matching placebo.[12] No study visit was scheduled/performed at week 5.[12]

Percentage of patients treated with Qelbree by dose (mg/day) at EOS (n=133)[12]



Mean dose at EOS (6 weeks) was 504 mg/day[4,12]

Methodology[4,12]: Randomized, DB, placebo-controlled, multicenter, parallel-group, flexible-dose study of adults 18 to 65 years of age with ADHD (Study P306). **Primary endpoint[12]:** CFB in AISRS Total Score at EOS. **Results[5]:** AISRS Total Score at EOS was significantly reduced in adults treated with Qelbree vs placebo. The CFB in AISRS Total Score at EOS (LS mean ± SE) was -15.5 ± 0.91 for Qelbree and -11.7 ± 0.90 for placebo.

Qelbree: the first nonstimulant approved for adult ADHD in 20 years[4,5]

Abbreviations: AISRS, ADHD Investigator Symptom Rating Scale; CFB, change from baseline; DB, double blind; EOS, end of study; LS mean, least-squares mean; SE, standard error.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

- Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
- Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

Please see full Important Safety Information on page 8.

Proven efficacy in treating ADHD at EOS (n=354)[5]

Inattention and hyperactivity/impulsivity symptom score reductions observed as early as week 2[4]

Study P306 (Adults 18 years and older)



No study visit was scheduled/performed at week 5.[4]

Study results

At baseline, the AISRS Total Score was comparable between groups: 38.5 for Qelbree and 37.6 for placebo. AISRS Total Score at EOS was significantly reduced with Qelbree vs placebo. The CFB in AISRS Total Score at EOS was -15.5 for Qelbree and -11.7 for placebo.[5]

ONCE-DAILY Qelbree® viloxazine extended-release capsules 100 mg 150 mg 200 mg

FRONT AND CENTER

Proven safety and tolerability across Phase III trial in male and female adults (n=372)[5]

Qelbree: Most common AEs (≥5% and twice the rate of placebo) reported by adults in the Phase III trial[5]

	Placebo (n=183)	Qelbree (n=189)
Insomnia*	7%	23%
Headache*	7%	17%
Fatigue	3%	12%
Nausea	3%	12%
Decreased appetite	3%	10%
Dry mouth	2%	10%
Somnolence*	2%	6%
Constipation	1%	6%

*The following items were combined:
- **Somnolence**: somnolence, lethargy, sedation
- **Headache**: headache, migraine, migraine with aura, tension headache
- **Insomnia**: initial insomnia, insomnia, middle insomnia, poor quality sleep, sleep disorder, terminal insomnia

AE discontinuation rates in adult trial[4,5]

Placebo	Qelbree
5%	9%

Qelbree additional safety information

- Viloxazine is unlikely to have a DDI with amphetamines or methylphenidate[5]
- No clinically relevant liver enzyme elevation[5]
- Treatment with Qelbree did not appear to have any influence on ECG changes[5]

Abbreviations: DDI, drug-drug interaction; ECG, electrocardiogram.

Consider the many needs of your adult female patients with ADHD[5]

Qelbree is the first ADHD treatment to meet its post-marketing requirement following the 2019 FDA guidance on clinical lactation studies[5]

In a study of 15 healthy **lactating women receiving Qelbree 600 mg for 3 days[5]:**

Relative infant dose (RID)[5]	
Viloxazine	~1%
Metabolite (5-HVLX-gluc)	~0.07%

†This study did not specifically evaluate the effects of viloxazine on breastfed infants or milk production, nor are there additional data regarding these effects. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Qelbree and any potential adverse effects on the breastfed child from Qelbree or from the underlying maternal condition.[5]

Transfer of Qelbree in breast milk is low[5†]

Qelbree offers adults with ADHD treatment versatility[5]

- **Qelbree** is prescribed once daily (AM or PM) for full 24-hour exposure.[4,5]
- **Qelbree** can be conveniently prescribed and refilled without a new prescription every month.[4,5]
- **Qelbree** has no known addiction potential or evidence of abuse.[5,13,14]
- **Qelbree—**Up to 90 days of treatment in 1 Rx! Patients pay as little as $20[‡] per Rx.
- **Qelbree** is available at pharmacies nationwide.[4]

[‡]Terms and conditions apply.

IMPORTANT SAFETY INFORMATION

- *Suicidal thoughts and behaviors*: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes

Please see full Important Safety Information on page 8.

ONCE-DAILY Qelbree® viloxazine extended-release capsules 100 mg 150 mg 200 mg

INDICATION

Qelbree is indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

CONTRAINDICATIONS

- Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
- Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

- *Suicidal thoughts and behaviors*: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
- *Heart rate, blood pressure increases*: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
- *Activation of mania or hypomania*: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression
- *Somnolence and fatigue*: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree

ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation.

PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg.

Please see full Prescribing Information, including Boxed Warning.

REFERENCES: 1. Russell J, Franklin B, Piff A, et al. Number of ADHD patients rising, especially among women. Epic Research. Published March 30, 2023. Accessed March 17, 2026. https://www.epicresearch.org/articles/number-of-adhd-patients-rising-especially-among-women **2.** Danielson ML, Bohm MK, Newsome K, et al. Trends in stimulant prescription fills among commercially insured children and adults — United States, 2016-2021. *MMWR Morb Mortal Wkly Rep*. 2023;72(13):327-332. doi:10.15585/mmwr.mm7213a1 **3.** Scoten O, Tabi K, Paquette V, et al. Attention-deficit/hyperactivity disorder in pregnancy and the postpartum period. *Am J Obstet Gynecol*. 2024;231(1):19-35. doi:10.1016/j.ajog.2024.02.297 **4.** Data on file, Supernus Pharmaceuticals, Inc. **5.** Qelbree [package insert]. Rockville, MD: Supernus Pharmaceuticals, Inc. **6.** Strattera [package insert]. Indianapolis, IN: Lilly USA, LLC. **7.** Clonidine extended release tablets: package insert / prescribing info. Drugs.com. Updated December 13, 2025. Accessed March 17, 2026. https://www.drugs.com/pro/clonidine-extended-release-tablets.html **8.** Intuniv [package insert]. Lexington, MA: Takeda Pharmaceuticals U.S.A. **9.** Ritalin [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. **10.** Adderall XR [package insert]. Horsham, PA: Teva Pharmaceuticals USA. **11.** Arnsten AFT. The emerging neurobiology of attention deficit hyperactivity disorder: the key role of the prefrontal association cortex. *J Pediatr.* 2009;154(5):I-S43. doi:10.1016/j.jpeds.2009.01.018. **12.** Nasser A, Hull JT, Chaturvedi SA, et al. A phase III, randomized, double-blind, placebo-controlled trial assessing the safety and efficacy of viloxazine estended-release capsules in adults with attention-deficit/hyperactivity disorder. *CNS Drugs*. 2022;36(8):897-915. doi:10.1007/s40263-022-00938-w **13.** Yanagita T, Wakasa Y, Kiyohara H. Drug dependence potential of viloxazine hydrochloride tested in rhesus monkeys. *Pharmacol Biochem Behav*. 1980;12:155-161. doi:10.1016/0091-3057(80)90430-x **14.** Key prescription stimulant label updates. U.S. Food and Drug Administration. May 11, 2023. Accessed March 17, 2026. https://www.fda.gov/media/168050/download

Supernus® Pharmaceuticals

ONCE-DAILY Qelbree® viloxazine
extended-release capsules
100 mg 150 mg 200 mg